



09 July 2021

ASX Announcement

## **CommSec Correction to Medlab Directors' Selling Shares**

Medlab (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines particularly in the field of oncology, today announces a correction to trading platform relating to regarding directors' shareholding dilution.

It was reported in the CommSec retail trading platform, on 25<sup>th</sup> March 2021, that two directors sold all their shares in MDC. The Company can confirm Directors Drew Townsend and Michael Hall **did not sell any shares during this period and still hold the same shareholding.**

A valued shareholder had brought this to Medlab's attention within the last 48 hours. After review with the shareholder, share registry, the ASX and with consultation with masters Hall and Townsend, it was confirmed they did not sell any shares from the period 1<sup>st</sup> January 2021 to 7<sup>th</sup> July 2021.

The notice, appearing on the CommSec trading platform, occurred post a capital raise that was performed during this period which diluted the shareholding of both abovementioned directors. Due to the dilution, the two major shareholders (>5%) have had their shares diluted due to the issue of new shares.

Morningstar have now resolved the reporting issue and adjusted the information under the "Shareholders" page in its retail trading platform.

ENDS

### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

### **About Medlab Clinical:**

Medlab Clinical LTD (ASX: MDC) is pioneering the development and Commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain. NanoCelle, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK. For more information, please visit [www.medlab.co](http://www.medlab.co)

**Medlab – better medicines, better patient care**

### **Contact:**

Medlab Clinical  
Dr. Sean Hall, CEO  
[sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

Medlab Clinical  
Kerem Kaya, CFO & Company Secretary  
[kerem\\_kaya@medlab.co](mailto:kerem_kaya@medlab.co)